BNT327
At WCLC 2025, pumitamig (BioNTech/BMS) demonstrated 76% ORR and 100% disease control in ES-SCLC, outperforming current PD-L1 monotherapies. The bispecific antibody combines checkpoint blockade and anti-angiogenesis for enhanced efficacy.
China biopharma
A decade of transformation in China’s biopharma industry: first-in-class drugs, expanded clinical pipelines, R&D talent, and billion-dollar global partnerships reshaping pharma leadership.
At WCLC 2025 (Sep 6–9), China-origin BNT327 (pumitamig), a PD-L1/VEGF-A bispecific, shows promising efficacy in first-line ES-SCLC. Abstract data were published Aug 20, 2025, marking the first global dataset for this China-origin therapy.